Henning Mann

ISSUE — 12 · OCTOBER 2026 Download PDF here: Prepared by Henning Mann, PhD | Founder & Principal, HM.BioConsulting In Collaboration with Kaela Siahpush, Pharmefex October 2026 | Version 1.0 INTRODUCTION Promising scientific innovations ranging from novel solutions in biotech, from consumables to bio- or medtech hardware to an actual innovative new drug can move from discovery toward pre- or clinical applications and assessments long before a young biotechnology company has built...

Download PDF here: An Interview between Ganakshi Gehlot, Vignesh Viswanathan, TissUse, and Henning Mann, PhD, HM.BioConsulting TissUse Authors: Ganakshi Gehlot, Vignesh Viswanathan HM.BioConsulting Authors: Desiree Goubert, Henning Mann Over the years of Assay Development in the MPS field, we have seen fluctuating interest in combining organs in in-vitro models: liver and kidney, for example, to reproduce toxic effects. Over the past decade, organ-on-chip has evolved from proof-of-concept...

HM.BioConsulting Spotlight Series ISSUE 10-1 · MAY 2026 A Strategic Intelligence Report by Henning Mann, HM.BioConsulting, Emma Aitken, Australian Trade & Investment Commission, Michael Phelan, InnovApproach Consulting Prepared by Henning Mann, PhD | Founder & Principal, HM.BioConsulting May 2026 Get the Full Article PDF EXECUTIVE SUMMARY Australia has quietly become a powerful launchpad for early-phase clinical development, and a rising hub for New Approach Methodologies (NAMs),...